SRB 5
Alternative Names: SRB-5Latest Information Update: 09 Jan 2026
At a glance
- Originator SunRock Biopharma
- Class Anti-inflammatories; Immunotherapies; Monoclonal antibodies
- Mechanism of Action CCR9 receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation